Form 4: Centessa Pharma Exec Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Centessa Pharmaceuticals' President of Orexin Program, Mario Alberto Accardi, sold 7,000 ordinary shares after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc, engaged in transactions on September 9, 2025.
- Accardi exercised options to acquire 5,000 ordinary shares at an exercise price of $8.01 per share.
- Concurrently, Accardi sold 7,000 ordinary shares at a price of $20.00 per share.
- The sale was executed under a Rule 10b5-1 trading plan, which was adopted on February 14, 2025.
- Following these transactions, Accardi's direct beneficial ownership of ordinary shares decreased from 212,566 to 205,566.
- Accardi retains 35,000 unexercised share options.
Sentiment
Score: 6
Explanation: The insider sale is mitigated by the fact it was pre-planned under a 10b5-1 plan, which reduces the implication of a negative signal. The executive also realized a significant profit from the option exercise.
Positives
- The exercise of options indicates a realization of value by the executive.
- The sale price of $20.00 per share is significantly higher than the exercise price of $8.01, indicating a profitable transaction for the executive.
Negatives
- An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Delegation | Gregory Weinhoff, an attorney-in-fact, appointed Raphael Deferiere as a substitute attorney-in-fact for several individuals, including Mario Alberto Accardi, to execute SEC Forms 3, 4, 5, Schedule 13D/G, and Form 144 filings. | 08/11/2025 | Streamlines the process for SEC filings for key personnel, ensuring timely compliance with reporting obligations. |
Related Party Transactions
- Mario Alberto Accardi, an officer of Centessa Pharmaceuticals, engaged in transactions involving the company's securities, which are considered related party transactions due to his insider status.
Stakeholder Impact
- Shareholders may view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The executive's continued significant holding (205,566 shares) still aligns interests.
- The delegation of Power of Attorney simplifies compliance for multiple executives.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | First installment vesting date for share options. |
| 02/14/2025 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 08/11/2025 | Date of Substitute Power of Attorney appointment. |
| 09/09/2025 | Date of option exercise and share sale transactions. |
| 09/11/2025 | Date the Form 4 was signed by attorney-in-fact. |
| 02/01/2034 | Expiration date for share options. |
Recommendation
holdWhile the insider sale might raise minor concerns, it was conducted under a pre-arranged 10b5-1 plan, suggesting it's not a reaction to new negative information. The executive still holds a substantial number of shares. Without further financial or operational updates, a 'hold' recommendation is appropriate, awaiting more comprehensive company performance data.
Keywords
Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Sale, Option Exercise, 10b5-1 Plan, Mario Alberto Accardi, Orexin Program, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.